Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec, BMS Advance Strategic Neuroscience Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Evotec, BMS Advance Strategic Neuroscience Pact

Key scientific achievement advances the joint neuroscience pipeline and Evotec earns a $25 million payment.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Evotec SE has made progress under a strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programs. Evotec receives a $25 million payment to progress further research.

Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases that slow down or reverse disease progression. This progress leverages Evotec’s PanOmics platform in conjunction with patient-derived disease models, which is one of the largest and most sophisticated platforms in the industry.
 
The partnership has generated a promising pipeline of discovery to clinical-stage programs. A first program, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021 as BMS-986419. In March 2023, Bristol Myers Squibb and Evotec extended and expanded their partnership for an additional 8 years.
 
Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said, “The achieved milestone underlines the productive nature of our neuroscience partnership with Bristol Myers Squibb. Using our PanOmics-driven drug discovery platform we are targeting neurodegenerative diseases with tremendous unmet medical need. Beyond BMS-986419, we are very excited to advance yet another program towards the clinic development in 2026.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics